Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study
- 741 Downloads
The purpose of this study was to evaluate the efficacy and safety of the low molecular weight heparin enoxaparin as anticoagulant in continuous veno-venous hemofiltration (CVVH) compared with unfractionated heparin.
Prospective randomized controlled crossover study.
Medical and Surgical Intensive Care Unit of a University Hospital.
Forty consecutive adult medical and surgical ICU patients with normal anticoagulation parameters requiring CVVH.
CVVH was performed with pre-filter fluid replacement at 2500 ml/h and blood flow rates of 180 ml/min. Heparin-treated patients received an initial pre-filter bolus of 30 IU/kg and a maintenance infusion at 7 units/kg h−1, titrated to achieve a systemic activated partial thromboplastin time (aPTT) of 40–45 s. Enoxaparin-treated patients received an initial pre-filter bolus of 0.15 mg/kg and a maintenance infusion starting at 0.05 mg/kg h−1, which was subsequently adjusted to maintain systemic anti-factor Xa activity (anti-Xa) at 0.25–0.30 IU/ml. Each patient received both regimens in a crossover design. Maximum treatment duration for each set was 72 h.
Patients included had a mean APACHE II score of 22 (10–35). Thirty-seven patients completed both study arms. Mean filter life span was 21.7 h (± 16.9 h) for heparin and 30.6 h (± 25.3) for enoxaparin (p = 0.017, ANOVA for repeated measures). One major bleeding episode occurred during heparin as well as during enoxaparin treatment. Cost analysis showed average daily costs of 270 and 240 € for heparin and enoxaparin, respectively.
Enoxaparin can be safely used for anticoagulation during CVVH resulting in higher filter lifespan compared with unfractionated heparin.
Keywordsanticoagulation CVVH renal replacement therapy costs safety unfractionated heparin low molecular weight heparin filter life span Enoxaparin
The study drug enoxaparin (Lovenox) was supplied at no charge by Aventis.
- 1.Ricci Z, Ronco C, D'Amico G, Felice R de, Rossi S, Bolgan I, Bonello M, Zamperetti N, Petras D, Salvatori G, Dan M, Piccinni P (2006) Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. Nephrol Dial Transplant 21:690–696PubMedCrossRefGoogle Scholar
- 5.Anastassiades E, Ireland H, Flynn A, Lane DA, Curtis JR (1990) A low-molecular-weight heparin (Kabi 2165, 'Fragmin') in repeated use for haemodialysis: prevention of clotting and prolongation of the venous compression time in comparison with commercial unfractioned heparin. Nephrol Dial Transplant 5:135–140PubMedGoogle Scholar
- 14.Lemaire F, Bion J, Blanco J, Damas P, Druml C, Falke K, Kesecioglu J, Larsson A, Mancebo J, Matamis D, Pesenti A, Pimentel J, Ranieri M (2005) The European Union Directive on Clinical Research: present status of implementation in EU member states' legislations with regard to the incompetent patient. Intensive Care Med 31:476–479PubMedCrossRefGoogle Scholar
- 20.Jochberger S, Mayr V, Luckner G, Fries DR, Mayr AJ, Friesenecker BE, Lorenz I, Hasibeder WR, Ulmer H, Schobersberger W, Dunser MW (2005) Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 9:R541–R548PubMedCrossRefGoogle Scholar
- 29.Becker RC, Spencer FA, Gibson M, Rush JE, Sanderink G, Murphy SA, Ball SP, Antman EM (2002) Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 143:753–759PubMedCrossRefGoogle Scholar
- 34.Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM (2003) Safety and efficacy of unfractioned heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 146:33–41PubMedCrossRefGoogle Scholar
- 39.Bouman CS, Oudemans-van Straaten HM, Tijssen JG, Zandstra DF, Kesecioglu J (2002) Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. Crit Care Med 30:2205–2211PubMedCrossRefGoogle Scholar